Latest Interviews
Showing 481–482 of 482 interview transcripts.
Clear all filters- a16z27 min
Shifting Risk Mindsets, from Tech to Bio
Jorge Conde, Vijay Pande, Jeff Low, Jeffrey Lowe
Bio-hybrid startups face critical challenges in translating novel technologies to traditional biological partners and avoiding the "death by a thousand pilots" trap through strategic deal structures. Founders must carefully position their platforms to capture value in high-impact areas like Phase III failure prediction while isolating asset risks via legal separation to prevent resource drain. Successful execution requires a hybrid approach to funding and partnership, where founders bridge the linguistic gap between tech and bio communities to align reimbursement models with long-term investor expectations.
- a16z22 min
Pande & Conde: When (and How) Biology Becomes Engineering
The bioindustry is undergoing a fundamental shift from stochastic discovery to design-driven engineering by treating biological systems as modular, interchangeable components akin to mechanical parts. This paradigm leverages interdisciplinary convergence, mature technologies like CRISPR, and machine learning to transform drug development into a reproducible, iterative process where platform value compounds over time. Consequently, pharmaceutical companies are redefining themselves as data-generating entities that prioritize scalable, predictive systems over single asset creation to achieve complex, long-term health goals.